Acitretin: Optimal dosing strategies

被引:35
作者
Ling, MR [1 ]
机构
[1] MedaPhase Inc, Atlanta, GA 30307 USA
关键词
D O I
10.1016/S0190-9622(99)70360-9
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Acitretin is an oral synthetic retinoid effective in the treatment of psoriasis. As monotherapy!: acitretin has been shown to be most effective in treating pustular and erythrodermic types of the disease. Monotherapy with acitretin for plaque-type psoriasis is often less successful; however, its use in combination with other therapies is highly effective in treating this form of the disease, Dose-response studies have established the effective dose range of acitretin as well as the dose-dependence of its side effects. Because both efficacy and side effects can vary substantially among individual patients, proper dosing of acitretin requires a balance between optimizing response and minimizing toxicity for each patient. Optimal dosing for individual patients may be achieved through a dose-escalation strategy involving initiation of therapy at low doses (10 to 25 mg/day) and, if necessary, gradually increasing the dose as tolerated until optimal response is achieved.
引用
收藏
页码:S13 / S17
页数:5
相关论文
共 11 条
[1]   BENEFIT OF PROGRESSIVELY INCREASING DOSES DURING THE INITIAL TREATMENT WITH ACITRETIN IN PSORIASIS [J].
BERBIS, P ;
GEIGER, JM ;
VAISSE, C ;
ROGNIN, C ;
PRIVAT, Y .
DERMATOLOGICA, 1989, 178 (02) :88-92
[2]   ACITRETIN AND ETRETINATE - HOW AND WHEN THEY SHOULD BE USED [J].
GEIGER, JM ;
SAURAT, JH .
DERMATOLOGIC CLINICS, 1993, 11 (01) :117-129
[3]   ACITRETIN (RO 10-1670, ETRETIN) - OVERALL EVALUATION OF CLINICAL-STUDIES [J].
GEIGER, JM ;
CZARNETZKI, BM .
DERMATOLOGICA, 1988, 176 (04) :182-190
[4]   ACITRETIN IMPROVES PSORIASIS IN A DOSE-DEPENDENT FASHION [J].
GOLDFARB, MT ;
ELLIS, CN ;
GUPTA, AK ;
TINCOFF, T ;
HAMILTON, TA ;
VOORHEES, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 18 (04) :655-662
[5]   ACITRETIN VERSUS ETRETINATE IN PSORIASIS - CLINICAL AND PHARMACOKINETIC RESULTS OF A GERMAN MULTICENTER STUDY [J].
GOLLNICK, H ;
BAUER, R ;
BRINDLEY, C ;
ORFANOS, CE ;
PLEWIG, G ;
WOKALEK, H ;
HOTING, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 19 (03) :458-468
[6]  
KRAGBALLE K, 1989, ACTA DERM-VENEREOL, V69, P35
[7]   TREATMENT OF SEVERE PSORIASIS WITH ETRETIN (RO-10-1670) [J].
LASSUS, A ;
GEIGER, JM ;
NYBLOM, M ;
VIRRANKOSKI, T ;
KAARTAMAA, M ;
INGERVO, L .
BRITISH JOURNAL OF DERMATOLOGY, 1987, 117 (03) :333-341
[8]   A 12-MONTH TREATMENT OF SEVERE PSORIASIS WITH ACITRETIN - RESULTS OF A CANADIAN OPEN MULTICENTER STUDY [J].
MURRAY, HE ;
ANHALT, AW ;
LESSARD, R ;
SCHACTER, RK ;
ROSS, JB ;
STEWART, WD ;
GEIGER, JM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (04) :598-602
[9]   A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ACITRETIN FOR THE TREATMENT OF PSORIASIS [J].
OLSEN, EA ;
WEED, WW ;
MEYER, CJ ;
COBO, LM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 21 (04) :681-686
[10]   Current use and future potential role of retinoids in dermatology [J].
Orfanos, CE ;
Zouboulis, CC ;
AlmondRoesler, B ;
Geilen, CC .
DRUGS, 1997, 53 (03) :358-388